Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), ...

2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

The upcoming interim Phase 1 data, expected in December, has generated optimism due to management’s confidence and the drug’s potential to outperform existing treatments like Dupixent. This optimism ...

Dupixent to Remain Sanofi's (SNY) Key Top-Line Driver The Zacks analyst expects Dupixent to remain Sanofi's key top-line driver as it enjoys strong demand trends. Sanofi has also accelerated its ...

A major news story from Sanofi this month is that "The European Medicines Agency has approved Dupixent (dupilumab) to treat ...